MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

827.28M

Vuru Grade

31.00/100

Current Price

$12.06
-0.09 (-0.74%)

Company Metrics

  • P/E 13.83
  • P/S 10.11
  • P/B 2.49
  • EPS -1.53
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / N/A %
  • Avg. Vol. 548,005.00
  • Shares 68.60M
  • Market Cap. 827.28M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?
Motley Fool - Aug 9, 2016
While the report included sales of Momenta's and partner Novartis AG's (NYSE:NVS) Glatopa, the generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) once-daily Copaxone, investors should focus on the potential approval of the generic ...
Momenta Pharmaceuticals Inc. (MNTA) President Sells $70677.60 in Stock
The Cerbat Gem - Aug 23, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 5,880 shares of the company's stock in a transaction on Monday, August 22nd.
Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 11.3% - Yahoo Finance
Momenta Pharmaceuticals Inc. (MNTA) SVP Sells $12411.50 in Stock - BBNS
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to ... - GlobeNewswire (press release)
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Given Average Rating of "Buy" by ...
The Cerbat Gem - Aug 17, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has been given a consensus recommendation of “Buy” by the ten brokerages that are covering the firm.
Analysts See Sales Of $297.395 For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Investor Newswire
Momenta Pharmaceuticals Inc. (MNTA) is Trading Higher on Unusual Volume for ...
Equities.com - Aug 16, 2016
Momenta Pharmaceuticals Inc. (MNTA) experienced unusually high volume on Aug. 15, as the stock gained 0.75% to a closing price of $12.06.
Pre-Market Trend Analysis Report: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA ...
Review Fortune - Aug 4, 2016
Momenta Pharmaceuticals, Inc.(NASDAQ:MNTA) stock dropped -14.82% in today's pre market session with the price of $10.00.
Cambridge-based Momenta halts pancreatic cancer drug trial - The Boston Globe
Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in ... - GlobeNewswire (press release)
Momenta Pharmaceuticals Inc. (MNTA) Issues Quarterly Earnings Results
The Cerbat Gem - Aug 5, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.32) by ...
Momenta Pharmaceuticals Inc. (MNTA) Jumps 11.92% on August 05 - Equities.com
Momenta Pharmaceuticals Inc. (MNTA) Receives Hold Rating from Cowen and Company - BBNS
Ligand Pharmaceuticals Incorporated versus Momenta Pharmaceuticals Inc Head to ...
CML News - Jul 20, 2016
Ligand Pharmaceuticals Incorporated has a substantially higher fundamental rating then Momenta Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Momenta Pharmaceuticals Inc. (MNTA) is Trading Lower on Unusual Volume for ...
Equities.com - Aug 26, 2016
Momenta Pharmaceuticals Inc. (MNTA) experienced unusually high volume on Aug. 25, as the stock lost 4.87% to a closing price of $12.71.